Evidence map›Paper›PMID 37851052›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.

Shira Tabachnick-Cherny, Thomas Pulliam, Haroldo J Rodriguez, Xinyi Fan, Daniel S Hippe, Daniel C Jones, Ata S Moshiri, Kimberly S Smythe, Rima M Kulikauskas, Lisa C Zaba and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Spatially organized inflammatory myeloid-CD8bioRxiv : the preprint server for biology · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Shira Tabachnick-ChernyDepartment of Dermatology, University of Washington, Seattle, Washington.ORCID 0000-0003-1595-4619
Thomas PulliamDepartment of Dermatology, University of Washington, Seattle, Washington.ORCID 0000-0003-3511-6348
Haroldo J RodriguezDepartment of Dermatology, University of Washington, Seattle, Washington.ORCID 0000-0002-1732-5747
Xinyi FanFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0008-0614-9099
Daniel S HippeFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-2427-4404
Daniel C JonesFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-7055-3119
Ata S MoshiriDepartment of Dermatology, New York University, New York, New York.ORCID 0000-0001-6684-4503
Kimberly S SmytheFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-2329-8298
Rima M KulikauskasDepartment of Dermatology, University of Washington, Seattle, Washington.ORCID 0000-0003-1092-1594
Lisa C ZabaDepartment of Dermatology, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0001-9036-5465
Kelly G PaulsonPaul G Allen Research Center, Providence-Swedish Cancer Institute, Seattle, Washington.ORCID 0000-0002-0033-3708
Paul NghiemDepartment of Dermatology, University of Washington, Seattle, Washington.ORCID 0000-0003-2784-963X
University of Washington · USFred Hutch Cancer Center · USNew York University · USPalo Alto University · USSwedish Medical Center · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Understand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI PAUL NGHIEM · 2019 to 2026
$22.7M
NCI NIH HHS P01 CA225517NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

purposeMerkel cell carcinoma (MCC) is a highly immunogenic skin cancer. Although essentially all MCCs are antigenic through viral antigens or high tumor mutation burden, MCC has a response rate of only approximately 50% to PD-(L)1 blockade suggesting barriers to T-cell responses. Prior studies of MCC immunobiology have focused on CD8 T-cell infiltration and their exhaustion status, while the role of innate immunity, particularly myeloid cells, in MCC remains underexplored. EXPERIMENTAL

designWe utilized single-cell transcriptomics from 9 patients with MCC and multiplex IHC staining of 54 patients' preimmunotherapy tumors, to identify myeloid cells and evaluate association with immunotherapy response.

resultsSingle-cell transcriptomics identified tumor-associated macrophages (TAM) as the dominant myeloid component within MCC tumors. These TAMs express an immunosuppressive gene signature characteristic of monocytic myeloid-derived suppressor cells and importantly express several targetable immune checkpoint molecules, including PD-L1 and LILRB receptors, that are not present on tumor cells. Analysis of 54 preimmunotherapy tumor samples showed that a subset of TAMs (CD163+, CD14+, S100A8+) selectively infiltrated tumors that had significant CD8 T cells. Indeed, higher TAM prevalence was associated with resistance to PD-1 blockade. While spatial interactions between TAMs and CD8 T cells were not associated with response, myeloid transcriptomic data showed evidence for cytokine signaling and expression of LILRB receptors, suggesting potential immunosuppressive mechanisms.

conclusionsThis study further characterizes TAMs in MCC tumors and provides insights into their possible immunosuppressive mechanism. TAMs may reduce the likelihood of treatment response in MCC by counteracting the benefit of CD8 T-cell infiltration. See related commentary by Silk and Davar, p. 1076.

Indexed as

Carcinoma, Merkel CellSkin NeoplasmsCD8-Positive T-LymphocytesHumansMyeloid CellsProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Receptor

Identifiers

PMID37851052
PMCPMC10947966
OpenAlexW4387728261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.